Challenges Remain, New Therapies Needed for Pediatric Lymphoblastic Lymphoma
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Improved Progression-Free Survival in Relapsed/Refractory Indolent Lymphoma With Lenalidomide Plus Rituximab
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
Pentostatin, Cyclophosphamide, Rituximab for Indolent Non-Hodgkin Lymphomas
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Results From a Phase 2 Study Evaluating Ofatumumab for Advanced-Stage Follicular Lymphoma
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Palbociclib Plus Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
A Novel Relapse Risk Stratification Model for Patients With Diffuse Large B-Cell Lymphoma
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Updated WHO-EORTC Classification for Primary Cutaneous Lymphomas
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Dose-Adjusted Immunochemotherapy May Yield Durable Remission in Aggressive Diffuse Large B-Cell Lymphoma
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
Researchers Report Early Clinical Promise for Macrophage Checkpoint Blockade
A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
CD19 CAR T-Cell Therapies: “Expect an Evolution”
“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.
Improved Outcomes for Vitreoretinal Lymphoma With Combined Treatment
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
CAR T Cell Therapy May Yield Durable Response in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.
Clinicians Face Uncertainties in Treating Older Patients With Hodgkin Lymphoma
A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.
First Rituximab Biosimilar Truxima Gets FDA Approval
The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.
Adcetris Plus Chemotherapy Approved for Peripheral T-Cell Lymphoma
The approval was based on data from a randomized, double-blind, double-dummy, actively controlled trial (ECHELON-2) involving 452 patients with certain PTCLs.
Standard Methodology Needed to Evaluate Pruritus in Cutaneous T Cell Lymphoma
Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.
Prognostic Value of Minimal Residual Disease in Indolent Lymphomas
Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.
Prevention of Hepatitis B Virus Reactivation in Patients With B-Cell Lymphoma
Preemptive nucleos(t)ide analog treatment (NAT) was associated with decreased risk of HBV reactivation in patients receiving immunochemotherapy.
Long-Term Survival in Patients With Advanced Stage Hodgkin Lymphoma
Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.
5-Azacitidine May Lead to Sustained Response in Peripheral T-Cell Lymphoma
Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.
Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
New Assay May Aid Identification of Primary Mediastinal B-Cell Lymphoma
The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.
Symptomatic Osteonecrosis as a Treatment Complication in Hodgkin Lymphoma
Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.
Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.
Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma
A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.
Insurance Status Influences Overall Survival in Follicular Lymphoma
Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).
All CAR Signaling Domains in Lymphoma Are Not Created Equal
Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.
Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma
Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.
Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma
A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.
Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
Imbruvica Plus Rituximab Approved for Waldenström’s Macroglobulinemia
This expanded approval was based on results from the iNNOVATE study, a double-blind, placebo-controlled trial evaluating Imbruvica in combination with rituximab vs placebo + rituximab in 150 patients with either relapsed/refractory disease or previously untreated Waldenström’s macroglobulinemia.
Soluble PD-1 Ligands May Contribute to the Pathogenesis of Waldenström Macroglobulinemia
New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.
Half-Dose R-CHOP May Be Effective, Reduce Toxicity, in Waldenström Macroglobulinemia
Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.
FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Ibrutinib Monotherapy Effective in CXCR4- and MYD88-Mutated Waldenström Macroglobulinemia
The effect of MYD88 and CXCR4 mutations on therapy response among patients with treatment-naïve Waldenström macroglobulinemia requires further investigation.
Waldenström Macroglobulinemia in Europe: Current Practices and Outcomes
A better understanding of current practices may lead to improved, standardized care, as well as better use of health care resources in Waldenström macroglobulinemia.
Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma
A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.
Fertility Preservation in Hodgkin’s Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.
Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.
Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.
Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma
Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator’s choice chemotherapy of CHOP, CVP, or bendamustine.
Want to read more?
Please login or register first to view this content.
